COVID-19

In response to the COVID-19 pandemic, IDCRP researchers activated an observational, longitudinal cohort study (Epidemiology, Immunology and Clinical Characteristics of Emerging Infectious Diseases with Pandemic Potential [EPICC]) at six military treatment facilities within the United States.  This study will capture clinical and laboratory data from patients with confirmed COVID-19 as well as persons under investigation to better understand the natural history of SARS-CoV-2 infection, including the clinical, virologic, and immunologic determinants of severe disease. Findings from this observational study will address numerous gaps in the current understanding of COVID-19 and support the development of treatment and prevention strategies that will not only benefit military personnel, but also civilian populations.  For more information, see the EPICC fact sheet below. 

In addition, IDCRP clinical research sites are participating in a adaptive, randomized-controlled trial to evaluate the efficacy of Remdesivir among individuals hospitalized with COVID-19 sponsored by the National Institute of Allergy and Infectious Diseases (https://clinicaltrials.gov/ct2/show/NCT04280705).  For more information, see the Adaptive COVID-19 Treatment Trial fact sheet below. 

/sites/default/files/IDCRP-085%20EPICC%20FACT%20SHEET_08Apr20.pdf

/sites/default/files/IDCRP-124%20ACTT%20FACT%20SHEET_v4_03-29-2020.pdf

 

IDCRP is committed to reducing the impact of infectious diseases in the military population through collaborative clinical research
Learn More >>